When compared to the individuals with HER2-zero levels, breast cancer with low HER2 levels exhibited an essential rise in the HR-positive rate (92.31% vs. 70.39%, p < 0.001) [24]. The gene discussed is ERBB2; the disease is breast carcinoma.